While Ascendis Pharma A/S ADR has underperformed by -0.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ASND rose by 54.07%, with highs and lows ranging from $229.94 to $118.03, whereas the simple moving average jumped by 16.85% in the last 200 days.
On November 18, 2025, Wolfe Research started tracking Ascendis Pharma A/S ADR (NASDAQ: ASND) recommending Peer Perform. A report published by Raymond James on October 17, 2025, Initiated its previous ‘Strong Buy’ rating for ASND. Morgan Stanley also rated ASND shares as ‘Overweight’, setting a target price of $250 on the company’s shares in an initiating report dated July 03, 2025. RBC Capital Mkts initiated its ‘Outperform’ rating for ASND, as published in its report on April 16, 2025. UBS’s report from January 07, 2025 suggests a price prediction of $196 for ASND shares, giving the stock a ‘Buy’ rating. Oppenheimer also rated the stock as ‘Outperform’.
Analysis of Ascendis Pharma A/S ADR (ASND)
Further, the quarter-over-quarter increase in sales is 292.94%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Ascendis Pharma A/S ADR’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. Taking into account the quick ratio of the company, currently set at 0.73, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ASND is recording an average volume of 549.85K. On a monthly basis, the volatility of the stock is set at 5.01%, whereas on a weekly basis, it is put at 6.52%, with a gain of 7.87% over the past seven days. Furthermore, long-term investors anticipate a median target price of $258.59, showing growth from the present price of $212.11, which can serve as yet another indication of whether ASND is worth investing in or should be passed over.
How Do You Analyze Ascendis Pharma A/S ADR Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.03%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 104.72% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
